IMR Press / RCM / Volume 22 / Issue 4 / DOI: 10.31083/j.rcm2204138
Open Access Review
Should paclitaxel be considered an old generation DCB? The limus era
Show Less
1 Cardiovascular Research Team, Clinica Polispecialistica San Carlo, 20037 Milano, Italy
2 Fondazione Ricerca e Innovazione Cardiovascolare, 20037 Milano, Italy
*Correspondence: (Bernardo Cortese)
Academic Editor: Marco Zimarino
Rev. Cardiovasc. Med. 2021, 22(4), 1323–1330;
Submitted: 29 July 2021 | Revised: 27 September 2021 | Accepted: 12 October 2021 | Published: 22 December 2021
(This article belongs to the Special Issue Drug-Coated balloons-The “leave nothing behind” strategy)
Copyright: © 2021 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license (

Since their introduction Drug Coated Balloons (DCBs) have slowly gained their spot into everyday cath-lab practice, first for treatment of in-stent restenosis (ISR), more recently for small vessels disease; today a growing body of evidence start supporting their use in more complex lesions, from bifurcations, to large vessels, to acute lesions. Although the new generation of DCBs showed a better performance and safety than the older one, the drug of choice has always been the Paclitaxel; last year some concerns were raised on the safety of Paclitaxel devices, in particular the balloons mining their use. Recently Sirolimus ventured in the DCBs world, making its appearance on cath-lab shelves and becoming a good alternative to Paclitaxel (DCB).

Fig. 1.
Back to top